Vyera and Martin Shkreli fail in bid to end Daraprim lawsuit
Defendant Martin Shkreli testifying before Congress in 2016; Wikipedia Commons/House Committee on Oversight and Government Reform
A federal judge in New York has ruled that Martin Shkreli and his company Vyera Pharmaceuticals must face an FTC lawsuit accusing them of scheming to maintain the company’s monopoly over antiparasitic drug Daraprim.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10